FDA/CMS Collaborations May Sidetrack Drug Development, Patient Access
Executive Summary
Manufacturers seeking simultaneous pathways for product approval and Medicare coverage determinations could trigger "endless loops of information requirements" during premarket development, according to Kay Holcombe, a senior policy advisor for Genzyme